Trevi Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic conditions.


The Company is pursuing several conditions for clinical development, including its lead indication of prurigo nodularis.

Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors
Brings over 30 years of experience working with emerging growth life sciences companies
Trevi Therapeutics Initiates Pivotal Clinical Trial of Nalbuphine ER for the Treatment of Pruritus in Prurigo Nodularis
Pruritus Relief thru Itch-Scratch Modulation (PRISM) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks